Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 341 - 360 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 18  19  20  21  22  23  24  25 »
Reset 

Cannabis Industry Pioneers Blockchain Adoption -- CFN Media

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018

48North Cannabis: A Vertically-Integrated Brand Portfolio Focused on Women -- CFN Media

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018

City View Green: A Promising New ACMPR Applicant About to Go Public -- CFN Media

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018

New U.S. Patent Allowance Granted to AXIM® Biotechnologies for Extraction and Purification of Delta-9-THC For Use in MedChew RX Clinical Program

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018
Related companies:  AXIM Biotechnologies, Inc.

United Health Products Files IDE Pre-Submission with the FDA for Approval to Begin Human Trials of HemoStyp®

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018

Pascal Biosciences Engages CFN Media to Build New Investor Audience

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018

High Hampton’s CoachellaGro is a GO as Management Eyes California Market -- CFN Media

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018

RavenQuest BioMed Expands Geographical Production Footprint -- CFN Media

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018

CareDx set to join Russell 2000, Russell 3000 and Russell Microcap Indexes

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018
Related companies:  CareDx, Inc.

Medtronic Introduces Updated iPro(TM)2 myLog App with FoodPrint(TM) Report Enhancing Diagnostic CGM for People with Diabetes

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018
Related companies:  Medtronic Plc

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018
Related companies:  Intellia Therapeutics, Inc.

Theratechnologies Announces Closing of US$57.5 Million Bought Deal Offering of 5.75% Convertible Unsecured Senior Notes

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018
Related companies:  THERATECHNOLOGIES, INC

Segra Commences Partnership with Original Breeders League for Micropropagation of High CBD Hemp and Cannabis

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018

Result of Annual General Meeting

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018
Related companies:  MOTIF BIOSCIENCES, INC.

Sera Prognostics Collaborates with Christiana Care Health System to Launch New Preterm Birth Study with PreTRM® Test

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018
Related companies:  SERA PROGNOSTICS

Medtronic Announces Scientific Data Presentations at the American Diabetes Association 78th Scientific Sessions Meeting

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018
Related companies:  Medtronic Plc

Spine Injury Solutions Announces Quad Video HALO in an upcoming national PBS TV segment

Read more ››
By: Nasdaq / GlobenewsWire - 19 Jun 2018
Related companies:  Spine Injury Solutions, Inc.

EVIO Inc. Appoints Felipe Campusano to Board of Directors

BEND, Ore., June 19, 2018 /CNW/ -- EVIO Inc. ("EVIO" or the "Company"), (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, is pleased to announce that Felipe Campusano... Read more ››

By: PR Newswire Association LLC. - 19 Jun 2018

Pivotal Study Reveals Effectiveness of Blood Tests in Screening for Sleep Apnea in Adult Males

BREA, Calif., June 19, 2018 /PRNewswire/ -- Beckman Coulter announced today the positive results of a clinical trial suggesting that blood tests may offer key benefits in the initial screening for obstructive sleep apnea. The study, which involved 264 male adult patients from six institutions,... Read more ››

By: PR Newswire Association LLC. - 19 Jun 2018
Related companies:  Beckman Coulter, Inc. (Brea, CA)

Luye Pharma Bolsters Its Global Analgesics Portfolio with China Class 1.1 New Compound LY03012 to Start Phase I Clinical Trials

SHANGHAI, June 19, 2018 /PRNewswire/ -- June 19, 2018, Luye Pharma Group announced that clinical applications of the company's new compound candidate, extended release tablets (''LY03012''), a China Class 1.1 new chemical drug, have been formally accepted by the China Food and Drug Administration.... Read more ››

By: PR Newswire Association LLC. - 19 Jun 2018
Related companies:  Luye Pharma Group | Luye Pharma AG
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17 18  19  20  21  22  23  24  25 »
to the top ↑